FDA Expedites Review for Ovarian Cancer Drug Candidate BI-1808

The FDA has granted Fast Track Designation to BioInvent International's BI-1808, an anti-TNFR2 antibody, for treating ovarian cancer in combination with pembrolizumab. This designation aims to accelerate the development and review process for drugs addressing serious conditions with unmet medical needs, based on promising interim Phase 2a results. This could potentially bring a new treatment option to patients sooner.